Destrier Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Destrier Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-104	Closed	-$248K	–	25
2014 Q4	$248K	Hold	104	–	–	0.07%	31
2014 Q3	$254K	Buy	+104	New	+$296K	0.06%	37

Other funds holding ELDN

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Destrier Capital Management's ELDN Position: Q1 2015 in Review

Destrier Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2015, closing a stake of 104 shares — an estimated $248K sold.

Destrier Capital Management first reported a position in ELDN in Q3 2014 and held it in 2 quarters. The position peaked at $254K in Q3 2014. 48 funds tracked by Wall St. Rank hold ELDN as of Q1 2015.

Destrier Capital Management reported no remaining Eledon Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Destrier Capital Management sold 104 Eledon Pharmaceuticals shares in Q1 2015, an estimated $248K.
Destrier Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 2 quarters.
Destrier Capital Management's Eledon Pharmaceuticals position peaked at $254K in Q3 2014.
48 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2015.

Based on Destrier Capital Management's 13F filing for Q1 2015, filed 14 May 2015.